Verona Pharma (VRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Ensifentrine is a promising supplementary therapeutic option in the management of chronic obstructive pulmonary disease (COPD), according to systematic review and meta-analysis findings published in ...

Two additional formulations of ensifentrine are currently in Phase 2 development for the treatment of COPD: dry powder inhaler ('DPI') and pressurized metered-dose inhaler ('pMDI').

Patients with acute COPD exacerbations are seen frequently in the emergency department (ED). Acute exacerbations are associated with significant morbidity, mortality and health care expenditures.

(Ensifentrine + glycopyrrolate) is under clinical development by Verona Pharma and currently in Phase II for Chronic Obstructive Pulmonary Disease (COPD). According to GlobalData, Phase II drugs for ...

Ensifentrine, marketed under the brand name Ohtuvayre, is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients. Ohtuvayre, which secured FDA ...

Ohtuvayre is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients. Ensifentrine (RPL-554) is under development for the treatment of allergic asthma ...